Department of Medicine
Education, Research, Clinical Care
The Hematology/Oncology Division faculty is committed to the three pillars of state-of-the-art patient care, research, and an outstanding training environment. We treat patients with all cancer types, and those with benign hematological disorders.
Providers, Residents & Fellows: find referral information and a clinical faculty & staff directory at Fletcher Allen Health Care.
Research & Education
The research mission of the Hematology/Oncology Division involves the exchange of knowledge from bench to bedside and back. Our research includes:
- Translational Research
- Epidemiology
- Clinical Research
- Public Health Research
We educate health care professionals at all levels of training, from medical and doctoral students to postdoctoral fellows, and members of the community.
Vermont Cancer Center
The Vermont Cancer Center is committed to innovative cancer research, life-saving prevention and treatment programs, public education and scientific collaboration, and serves to optimize cancer prevention, screening, diagnosis and care across Vermont and northern New York.
Recent Grant Funding
February 2012
Mary Cushman, MD, University of California, San Diego, Abdominal Body Composition, Inflammation and Cardiovascular Disease, $23,732; University of Alabama at Birmingham,
Etiology of Geographic and Racial Differences in Stroke , $142,190; University of Pittsburgh, Exceptional Survival: Trajectories to Functional Aging (CHS All Stars), $289,152
Claire F. Verschraegen, MD, Lake Champlain Cancer Research Organization, Lake Champlain Cancer Research, $640,000
Chris Holmes, M.D., Ph.D.
Holmes Contributes to Myelofibrosis Research in New England Journal of Medicine
A new study in the New England Journal of Medicine offers a glimmer of hope for some patients with myelofibrosis, a rare, yet life-threatening blood cancer that leads to a build-up of scar tissue in the bone marrow.
Chris Holmes, M.D., Ph.D., associate professor of medicine and a hematologist/oncologist at the University of Vermont College of Medicine, led the COMFORT-I (Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment I) multicenter trial, which compared ruxolinitib to placebo, at the Vermont Cancer Center at UVM and Fletcher Allen. "This study showed that patients who took the drug had an improvement in their quality of life and a reduction in the size of their spleen," says Holmes. "By participating in this study, we were able to get this drug to our patients faster."
(Article by Jennifer Nachbur; Photo by Mario Morgado)
Last modified May 10 2012 01:32 PM
